Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 7/20 | 0.37 |
| ▸ | RXRA | P19793 | 6/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 6/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30890622 | 0.87 | NR1H2 (0.38) | NR1H2RXRANR1H3BRD4CREBBP | |
| SCHEMBL27245054 | 0.86 | CNR2 (0.35) | CNR2 | |
| SCHEMBL30992272 | 0.85 | NR1H2 (0.43) | NR1H2RXRANR1H3BRD4CREBBP | |
| SCHEMBL27244833 | 0.85 | NR1H2 (0.36) | NR1H2RXRANR1H3BRD4CREBBP | |
| SCHEMBL30890482 | 0.83 | POLB (0.40) | NR1H2RXRANR1H3BRD4CREBBP | |
| SCHEMBL30890677 | 0.79 | OTUD7B (0.43) | NR1H2RXRANR1H3EPHX2 | |
| SCHEMBL30992283 | 0.76 | CCNB2 (0.36) | NR1H2RXRANR1H3BRD4 | |
| SCHEMBL30890744 | 0.76 | AKR1B1 (0.35) | NR1H2RXRANR1H3 | |
| SCHEMBL30890668 | 0.76 | OTUD7B (0.35) | NR1H2RXRANR1H3 | |
| SCHEMBL30890725 | 0.76 | NR1H2 (0.42) | NR1H2RXRANR1H3BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612156-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-20 | — | — | US | disclosed |
| WO-2024097296-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | NR1H2 449/4885RXRA 3055/4885NR1H3 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.